HK Stock Market Move | Maiwei biology-B (02493) rose more than 6% in the morning, the clinical trial application for injection 6MW5311 has obtained FDA approval.

Meiwei Biologic-B (02493) rose more than 6% in the morning, as of the time of writing, it rose by 6.22%, with a price of 26.66 Hong Kong dollars and a turnover of 12.5609 million Hong Kong dollars. In terms of news, Meiwei Biologic-B announced that recently, Meiwei (Shanghai) Biotech Co., Ltd. (referred to as the "Company") received the "Study May Proceed Notification" issued by the Food and Drug Administration (FDA) of the United States. The clinical trial application for the use of injectable 6MW5311 for indications of hematologic malignancies (acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM)) has officially received FDA approval. In addition, the 6MW5311 clinical trial application has been accepted by the National Medical Products Administration. 6MW5311 adopts a "2+1" asymmetric molecular structure, targeting both LILRB4 and CD3, forming an immune synapse by bridging tumor cells and T cells, activating T cells, and efficiently killing tumors. This molecule significantly reduces the binding activity of CD3 antibodies to T cells in the absence of tumor cells through the introduction of a unique spatial steric hindrance design, selectively activating T cells only when tumor cells are present, thereby greatly enhancing the anti-tumor efficacy while significantly improving safety.